Cited by 693Advanced Drug Delivery SystemsRetinal Diseases and TreatmentsOcular Infections and Treatments

The DOI matches its Crossref record; 476 of the 476 references it cites were found in a registry or an index.

Pharmacokinetic aspects of retinal drug delivery

Open access

del Amo, Eva M., Rimpelä, Anna-Kaisa, Heikkinen, Emma, Kari, Otto K., Ramsay, Eva, Lajunen, Tatu, Schmitt, Mechthild, Pelkonen, Laura, Bhattacharya, Madhushree, Richardson, Dominique, Subrizi, Astrid, Turunen, Tiina, Reinisalo, Mika, Itkonen, Jaakko, Toropainen, Elisa, Casteleijn, Marco, Kidron, Heidi, Antopolsky, Maxim, Vellonen, Kati-Sisko, Ruponen, Marika, Urtti, Arto·2017·Progress in Retinal and Eye Research

DOI 10.1016/j.preteyeres.2016.12.001

Open this paper in CoChat — free account Open PDF

Abstract

Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.preteyeres.2016.12.001

Cites

476 of 476 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.
Boussif, O., Lezoualc’h, F., Zanta, M. A., Djavaheri‐Mergny, M., Scherman, D., DEMENEIX, B. A., & Behr, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,256
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,545
Regulated portals of entry into the cell
Conner, S. D., & Schmid, S. L. (2003) · Nature · doi:10.1038/nature01451 · Cited by 3,959
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145

Flagged first, then by citations

Show all 476 references

Research works printed but not linked: 7

Barza, 1982, The effects of infection and probenecid on the transport of carbenicillin from the rabbit vitreous humor. Investig. Ophthalmol, Vis. Sci., 22, 720
Gisladottir, 2009, Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefe's Arch. Clin. Exp, Ophthalmol, 247, 1677
Haselton, 1996, Modulation of retinal endothelial barrier in a perfused cell-column model of the retinal microvasculature, Investig. Ophthalmol. Vis. Sci., 37, 211
Johnson, 1984, vol. 39, 791
Szebeni, 2005, Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity, Toxicology, 216, 106, 10.1016/j.tox.2005.07.023 · DOI
Szebeni, 2011, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev., 63, 1020, 10.1016/j.addr.2011.06.017 · DOI
U.S. Food and Drug Administration, 2013, Guidance for industry: immunogenicity assessment for therapeutic protein products, Biotechnol. Law Rep., 172

Sorted by citations

Items 101–200 of 693

Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye
Wang, Y., & Wang, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061150 · Cited by 48
HDAC inhibition ameliorates cone survival in retinitis pigmentosa mice
Samardzija, M., Corna, A., Gomez-Sintes, R., Jarboui, M. A., Armento, A., Roger, J. E., Petridou, E., Haq, W., Paquet-Durand, F., Zrenner, E., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00653-3 · Cited by 48
Nanoscale calcium oxide and its biomedical applications: A comprehensive review
Kumari, M., Sarkar, B., & Mukherjee, K. (2022) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2022.102506 · Cited by 49
Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment
Loftsson, Þ., & Stefánsson, E. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14861 · Cited by 48
Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges
Lau, C. M. L., Yu, Y., Jahanmir, G., & Chau, Y. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.013 · Cited by 46
Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing
Jung, J. H., Desit, P., & Prausnitz, M. R. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23758 · Cited by 46
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
Tolone, A., Belhadj, S., Rentsch, A., Schwede, F., & Paquet‐Durand, F. (2019) · Genes · doi:10.3390/genes10060453 · Cited by 46
Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
Hyaluronic Acid-Based Gold Nanoparticles for the Topical Delivery of Therapeutics to the Retina and the Retinal Pigment Epithelium
Laradji, A. M., Karakoçak, B. B., Kolesnikov, A. V., Kefalov, V. J., & Ravi, N. (2021) · Polymers · doi:10.3390/polym13193324 · Cited by 48
Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress
Shen, Y., Sun, J., & Sun, X. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01838-x · Cited by 45
Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation
Ramsay, E., Hagström, M., Vellonen, K., Boman, S., Toropainen, E., del Amo, E. M., Kidron, H., Urtti, A. O., & Ruponen, M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.08.008 · Cited by 45
Self-citation
Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers
de Oliveira, I. F., Barbosa, E. J., Peters, M. C. C., Henostroza, M. A. B., Yukuyama, M. N., Neto, E. D. S., Löbenberg, R., & Bou‐Chacra, N. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119831 · Cited by 45
A review on revolutionizing ophthalmic therapy: Unveiling the potential of chitosan, hyaluronic acid, cellulose, cyclodextrin, and poloxamer in eye disease treatments
Wang, T.-J., Rethi, L., Ku, M.-Y., Nguyen, H. T., & Chuang, E. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132700 · Cited by 47
Surface functionalized mesoporous silica nanoparticles for intravitreal application of tacrolimus
de Paiva, M. R. B., Andrade, G. F., Dourado, L. F. N., Castro, B. F. M., Fialho, S. L., de Sousa, E. M. B., & Silva‐Cunha, A. (2020) · Journal of Biomaterials Applications · doi:10.1177/0885328220977605 · Cited by 44
Intravitreal Polymeric Nanocarriers with Long Ocular Retention and Targeted Delivery to the Retina and Optic Nerve Head Region
Junnuthula, V., Sadeghi, A., Cao, S., Tavakoli, S., Ridolfo, R., Toropainen, E., Ruponen, M., van Hest, J. C. M., & Urtti, A. O. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040445 · Cited by 44
Self-citation
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration
Adams, C. M., Anderson, K., Artman, G. D., Bizec, J.-C., Cepeda, R., Elliott, J. M., Fassbender, E. S., Ghosh, M., Hanks, S. M., Hardegger, L. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01731 · Cited by 44
Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Mietzner, R., Kade, C., Froemel, F., Pauly, D., Stamer, W. D., Ohlmann, A., Wegener, J., Fuchshofer, R., & Breunig, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080706 · Cited by 43
Emerging therapies and their delivery for treating age‐related macular degeneration
Thomas, C. N., Sim, D. A., Lee, W. H., Alfahad, N., Dick, A. D., Denniston, A. K., & Hill, L. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15459 · Cited by 46
Medical and Surgical Applications for the Suprachoroidal Space
Emami-Naeini, P., & Yiu, G. (2019) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000251 · Cited by 41
Topical drug delivery to the retina: obstacles and routes to success
Loftsson, Þ. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2017878 · Cited by 41
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault‐Sabourin, C., Joubert, N., Pouget, J., Gouilleux‐Gruart, V., Heuzé‐Vourc'h, N., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 43
Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study
Stefánsson, E., Loftsson, T., Larsen, M., Papp, A., Kaarniranta, K., Munk, M. R., Dugel, P. U., Tadayoni, R., & DX‐211 study group (2022) · Acta Ophthalmologica · doi:10.1111/aos.15215 · Cited by 39
Establishment of an In Vitro–In Vivo Correlation for Melanin Binding and the Extension of the Ocular Half-Life of Small-Molecule Drugs
Jakubiak, P., Cantrill, C., Urtti, A. O., & Alvarez‐Sánchez, R. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00769 · Cited by 39
Self-citation
Safety and Biocompatibility of Aflibercept-Loaded Microsphere Thermo-Responsive Hydrogel Drug Delivery System in a Nonhuman Primate Model
Kim, S.-H., Kang‐Mieler, J. J., Liu, W., Wang, Z., Yiu, G. C., Teixeira, L. B. C., Mieler, W. F., & Thomasy, S. M. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.30 · Cited by 39
Micelles of progesterone for topical eye administration: interspecies and intertissues differences in Ex vivo ocular permeability
Alambiaga-Caravaca, A. M., Calatayud-Pascual, M. A., Rodilla, V., Concheiro, A., López-Castellano, A., & Alvarez-Lorenzo, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080702 · Cited by 38
Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases
Hashida, N., & Nishida, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114870 · Cited by 37
Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts
Pelkonen, L., Tengvall, U., Ruponen, M., Kidron, H., del Amo, E. M., Reinisalo, M., & Urtti, A. O. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.027 · Cited by 38
Self-citation
Extended Pharmacokinetic Model of the Rabbit Eye for Intravitreal and Intracameral Injections of Macromolecules: Quantitative Analysis of Anterior and Posterior Elimination Pathways
Lamminsalo, M., Taskinen, E., Karvinen, T., Subrizi, A., Murtomäki, L. S., Urtti, A. O., & Ranta, V. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2435-0 · Cited by 38
Self-citation
Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema
Wong, C. W., & Wong, T. T. L. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313462 · Cited by 38
Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy
Delgado‐Tirado, S., Amarnani, D., Zhao, G., Rossin, E. J., Eliott, D., Miller, J. B., Greene, W. A., Ramos, L., Arévalo-Alquichire, S., Leyton-Cifuentes, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77254-0 · Cited by 39
Recent development of polymer nanomicelles in the treatment of eye diseases
Cai, R., Zhang, L., & Hao, C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1246974 · Cited by 40
Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles
Huang, X., & Chau, Y. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107711 · Cited by 37
Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds
Rafael, D. F. D. S., Guerrero, M., Maricán, A., Arango, D., Sarmento, B. F. C. C., Ferrer, R., Durán‐Lara, E. F., Clark, S. J., & Schwartz, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051484 · Cited by 37
Extracellular vesicles in degenerative retinal diseases: A new therapeutic paradigm
Manai, F., Smędowski, A., Kaarniranta, K., Comincini, S., & Amadio, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.035 · Cited by 37
Aflibercept Nanoformulation Inhibits VEGF Expression in Ocular In Vitro Model: A Preliminary Report
Kelly, S. J., Hirani, A., Shahidadpury, V., Solanki, A., Halasz, K., Gupta, S. V., Madow, B., & Sutariya, V. B. (2018) · Biomedicines · doi:10.3390/biomedicines6030092 · Cited by 36
Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection
Zhang, Y., Bazzazi, H., Silva, R. L. E., Pandey, N. B., Green, J. J., Campochiaro, P. A., & Popel, A. S. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23632 · Cited by 36
Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
Sarkar, A., Junnuthula, V., & Dyawanapelly, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910594 · Cited by 40
Acute and continuous exposure of airborne fine particulate matter (PM2.5): diverse outer blood–retinal barrier damages and disease susceptibilities
Gu, Y., Sheng, F., Gao, M., Zhang, L., Hao, S., Chen, S., Chen, R., Xu, Y., Wu, D., Han, Y., et al. (2023) · Particle and Fibre Toxicology · doi:10.1186/s12989-023-00558-2 · Cited by 35
Ophthalmic Magnetic Resonance Imaging: Where Are We (Heading To)?
Niendorf, T., Beenakker, J. M., Langner, S., Erb‐Eigner, K., Cuadra, M. B., Beller, E., Millward, J. M., Niendorf, T. M., & Stachs, O. (2021) · Current Eye Research · doi:10.1080/02713683.2021.1874021 · Cited by 35
Human immunocompetent choroid-on-chip: a novel tool for studying ocular effects of biological drugs
Cipriano, M., Schlünder, K., Probst, C., Linke, K., Weiß, M., Fischer, M. J., Mesch, L., Achberger, K., Liebau, S., Mesquida, M., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02977-3 · Cited by 35
Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina
Muya, L. W., Kansara, V. S., Cavet, M. E., & Ciulla, T. A. (2022) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.0090 · Cited by 35
Understanding Molecular Drivers of Melanin Binding To Support Rational Design of Small Molecule Ophthalmic Drugs
Jakubiak, P., Reutlinger, M., Mattei, P., Schuler, F., Urtti, A. O., & Alvarez‐Sánchez, R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01281 · Cited by 35
Self-citation
Research progress of photo-crosslink hydrogels in ophthalmology: A comprehensive review focus on the applications
Zhang, Q., Yan, K., Zheng, X., Liu, Q., Han, Y., & Liu, Z. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101082 · Cited by 35
Delivery of Antisense Oligonucleotides to the Cornea
Chau, V. Q., Hu, J., Gong, X., Hulleman, J. D., Ufret-Vincenty, R. L., Rigo, F., Prakash, T. P., Corey, D. R., & Mootha, V. V. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0838 · Cited by 35
Preclinical challenges for developing long acting intravitreal medicines
Awwad, S., Henein, C., Ibeanu, N., Khaw, P. T., & Brocchini, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.05.005 · Cited by 33
Release of functional dexamethasone by intracellular enzymes: A modular peptide-based strategy for ocular drug delivery
Bhattacharya, M., Sadeghi, A., Sarkhel, S., Hagström, M., Bahrpeyma, S., Toropainen, E., Auriola, S. O. K., & Urtti, A. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.005 · Cited by 33
Self-citation
Perspectives of Molecularly Imprinted Polymer-Based Drug Delivery Systems in Ocular Therapy
Bodoki, A., Iacob, B., Dinte, E., Voștinaru, O., Samoilă, O., & Bodoki, E. (2021) · Polymers · doi:10.3390/polym13213649 · Cited by 33
Self-Healing Thermosensitive Hydrogel for Sustained Release of Dexamethasone for Ocular Therapy
Annala, A., Ilochonwu, B. C., Wilbie, D., Sadeghi, A., Hennink, W. E., & Vermonden, T. (2022) · ACS Polymers Au · doi:10.1021/acspolymersau.2c00038 · Cited by 32
RETRACTED: Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks
Ashique, S., Mishra, N., Mohanto, S., Gowda, B. H. J., Kumar, S., Raikar, A. S., Masand, P., Garg, A., Goswami, P. K., & Kahwa, I. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23810 · Cited by 32
Retracted
Next generation therapeutics for retinal neurodegenerative diseases
Appell, M. B., Pejavar, J., Pasupathy, A., Rompicharla, S. V. K., Abbasi, S., Malmberg, K., Kolodziejski, P., & Ensign, L. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.063 · Cited by 33
Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management
Zhou, Y., Xu, M., Shen, W., Xu, Y., Shao, A., Xu, P., Yao, K., Han, H., & Ye, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304626 · Cited by 33
Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases
Shatz-Binder, W., Aaronson, J., Yohe, S. T., Kelley, R. F., & Kalia, Y. N. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1553953 · Cited by 32
Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery
Urimi, D., Widenbring, R., García, R. O. P., Gedda, L., Edwards, K., Loftsson, Þ., & Schipper, N. G. M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120640 · Cited by 32
A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future
Conrady, C. D., & Yeh, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081224 · Cited by 34
Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations
del Amo, E. M., Hammid, A., Tausch, M., Toropainen, E., Sadeghi, A., Valtari, A., Puranen, J., Reinisalo, M., Ruponen, M., Urtti, A. O., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121361 · Cited by 31
Self-citation
How to Manage a Patient with Ocular Metastases?
Thariat, J., Boudin, L., Loria, O., Nguyen, A.-M., Kodjikian, L., & Mathis, T. (2022) · Biomedicines · doi:10.3390/biomedicines10123044 · Cited by 31
Neurofilament light is a treatment‐responsive biomarker in CLN2 disease
Ru, Y., Corado, C. R., Soon, R. K., Melton, A. C., Harris, A., Yu, G. K., Pryer, N., Sinclair, J. R., Katz, M. L., Ajayi, T., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50942 · Cited by 30
Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics
Cong, Y.-Y., Fan, B., Zhang, Z.-Y., & Li, G. (2023) · International Ophthalmology · doi:10.1007/s10792-023-02637-x · Cited by 30
Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease
Faria, M. J., González‐Méijome, J. M., Oliveira, M. E. C. D. R., Carracedo, G., & Lúcio, M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115321 · Cited by 31
Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis
Luaces-Rodríguez, A., González‐Barcia, M., Blanco‐Teijeiro, M. J., Gil‐Martínez, M., González, F., Gómez‐Ulla, F., Lamas, M. J., Otero-Espinar, F. J., & Fernández‐Ferreiro, A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020066 · Cited by 30
Entrapment of drug-sorbate complex in submicron emulsion: A potential approach to improve antimicrobial activity in bacterial corneal infection
Pandey, D. P., Kesharwani, P., & Jain, D. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.006 · Cited by 30
Recent developments in liposomal drug delivery systems for the treatment of retinal diseases
Urquhart, A. J., & Eriksen, A. Z. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.004 · Cited by 30
The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane
Devoldere, J., Wels, M., Peynshaert, K., Dewitte, H., Smedt, S. C. D., & Remaut, K. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.023 · Cited by 30
Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review
Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 31
Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury
Fouda, A. Y., Eldahshan, W., Xu, Z., Lemtalsi, T., Shosha, E., Zaidi, S. A. H., Abdelrahman, A. A., Cheng, P. N.-M., Narayanan, S. P., Caldwell, R. W., et al. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113923 · Cited by 28
Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases
Liu, X., Huang, K., Zhang, F., Huang, G., Wang, L., Wu, G., Ren, H., Yang, G., & Lin, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02614-1 · Cited by 29
Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space
Wakshull, E., Quarmby, V. E., Mahler, H., Rivers, H. M., Jere, D., Ramos, M. F., Szczesny, P. J., Bechtold-Peters, K., Masli, S., & Gupta, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0128-y · Cited by 29
Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits
Bussing, D., & K. Shah, D. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09713-0 · Cited by 29
Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye
Fayyaz, A., Vellonen, K., Ranta, V., Toropainen, E., Reinisalo, M., Valtari, A., Puranen, J., Ricci, G. D., Heikkinen, E. M., Gardner, I. B., et al. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.06.003 · Cited by 29
Self-citation
Imaging, quantitation and kinetic modelling of intravitreal nanomaterials
Sadeghi, A., Ruponen, M., Puranen, J., Cao, S., Ridolfo, R., Tavakoli, S., Toropainen, E., Lajunen, T., Ranta, V., van Hest, J. C. M., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121800 · Cited by 29
Self-citation
Emerging strategies of engineering retinal organoids and organoid-on-a-chip in modeling intraocular drug delivery: Current progress and future perspectives
Yu, J., Yin, Y., Leng, Y., Zhang, J., Wang, C., Chen, Y., Li, X., Wang, X., Liu, H., Liao, Y., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114842 · Cited by 31
Sustained Inhibition of VEGF and TNF-α Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma
Zhou, C., Lei, F., Sharma, J., Hui, P., Wolkow, N., Dohlman, C. H., Vavvas, D. G., Chodosh, J., & Paschalis, E. I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082059 · Cited by 29
Extended release of dexamethasone from oleogel based rods
Macoon, R., Guerriero, T., & Chauhan, A. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.07.082 · Cited by 28
Triamcinolone Acetonide-Loaded PEGylated Microemulsion for the Posterior Segment of Eye
Nayak, K., & Misra, M. (2020) · ACS Omega · doi:10.1021/acsomega.9b04244 · Cited by 28
Patient preferences in retinal drug delivery
Jacobs, B., Palmer, N., Shetty, T., Dimaras, H., Hajrasouliha, A. R., Jusufbegovic, D., & Corson, T. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-98568-7 · Cited by 28
In vitro and computational modelling of drug delivery across the outer blood–retinal barrier
Davies, A., Williams, R., Lugano, G., Pop, S. R., & Kearns, V. (2020) · Interface Focus · doi:10.1098/rsfs.2019.0132 · Cited by 27
Titanium dioxide nanoparticles impair the inner blood-retinal barrier and retinal electrophysiology through rapid ADAM17 activation and claudin-5 degradation
Chan, Y.-J., Liao, P.-L., Tsai, C.-H., Cheng, Y.-W., Lin, F., Ho, J., Chen, C., & Li, C.-H. (2021) · Particle and Fibre Toxicology · doi:10.1186/s12989-020-00395-7 · Cited by 27
Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues
Hammid, A., Fallon, J. K., Lassila, T., Salluce, G., Smith, P. C., Tolonen, A., Sauer, A., Urtti, A. O., & Honkakoski, P. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01154 · Cited by 27
Self-citation
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases
Bohley, M., Dillinger, A. E., Tamm, E. R., & Göpferich, A. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.024 · Cited by 28
Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration
Ruiz, E. A. C., Swindle‐Reilly, K. E., & Versypt, A. N. F. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.021 · Cited by 27
Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics
Singh, M. P., Negi, R., Alka, Vinayagam, R., Kang, S. G., & Shukla, P. (2024) · Medicina · doi:10.3390/medicina60101647 · Cited by 29
Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone
Stein, S., Auel, T., Kempin, W., Bogdahn, M., Weitschies, W., & Seidlitz, A. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.02.034 · Cited by 26
Pharmacokinetics of Pullulan–Dexamethasone Conjugates in Retinal Drug Delivery
Kicková, E., Sadeghi, A., Puranen, J., Tavakoli, S., Sen, M., Ranta, V., Arango‐González, B., Bolz, S., Ueffing, M., Salmaso, S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010012 · Cited by 26
Self-citation
Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
Causative glaucoma treatment: promising targets and delivery systems
Mietzner, R., & Breunig, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.017 · Cited by 26
Recent advances in slow and sustained drug release for retina drug delivery
Béhar‐Cohen, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1618829 · Cited by 26
Intravitreal Pharmacokinetics in Mice: SPECT/CT Imaging and Scaling to Rabbits and Humans
Schmitt, M., Hippeläinen, E. T., Raviña, M., Arango‐González, B., Antopolsky, M. L., Vellonen, K., Airaksinen, A. J., & Urtti, A. O. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00679 · Cited by 26
Self-citation
Protection of human retinal pigment epithelial cells from oxidative damage using cysteine prodrugs
Kularatne, R. N., Bulumulla, C., Catchpole, T., Takacs, A., Christie, A. H., Stefan, M. C., & Csaky, K. G. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.03.024 · Cited by 26
Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects
Bakri, S. J., Lynch, J., Howard-Sparks, M., Saint-Juste, S., & Saïm, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304782 · Cited by 26
Nanomedicine in Ophthalmology: From Bench to Bedside
Mahaling, B., Baruah, N., & Dinabandhu, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247651 · Cited by 25
Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Sonntag, T., Froemel, F., Stamer, W. D., Ohlmann, A., Fuchshofer, R., & Breunig, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060901 · Cited by 25
Looking for In Vitro Models for Retinal Diseases
Alfonsetti, M., Castelli, V., d’Angelo, M., Benedetti, E., Allegretti, M., Barboni, B., & Cimini, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910334 · Cited by 27
In vitro Model Systems for Studies Into Retinal Neuroprotection
Zhu, Y., Cao, B., Tolone, A., Yan, J., Christensen, G., Arango‐González, B., Ueffing, M., & Paquet‐Durand, F. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.938089 · Cited by 24
Retinal Delivery of the Protein Kinase C-β Inhibitor Ruboxistaurin Using Non-Invasive Nanoparticles of Polyamidoamine Dendrimers
Alshammari, R. A., Aleanizy, F. S., Aldarwesh, A., Alqahtani, F. Y., Mahdi, W. A., AlQuadeib, B. T., Alqahtani, Q. H., Haq, N., Shakeel, F., Abdelhady, H. G., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071444 · Cited by 25
Comparative Study of In Situ Loaded Antibody and PEG‐Fab NIPAAM Gels
Awwad, S., Al-Shohani, A. D. H., Khaw, P. T., & Brocchini, S. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700255 · Cited by 25
Liposome‐Based Permeable Eyedrops for Effective Posterior Segment Drug Delivery
Wang, Y., Hu, Y., An, J., Zhang, H., Liu, X., Li, X., Zhang, Z., & Zhang, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202403142 · Cited by 25
Mathematical Models of Ocular Drug Delivery
Sadeghi, A., Subrizi, A., del Amo, E. M., & Urtti, A. O. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.11.28 · Cited by 26
Self-citation
Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management
Pardeshi, S. R., Gholap, A. D., Hatvate, N. T., Gharat, K. D., Naik, J., & Omri, A. (2024) · Discover Nano · doi:10.1186/s11671-024-04154-x · Cited by 24
Recent advances in engineered exosome-based therapies for ocular vascular disease
Guan, J., Meng, F., Wang, C., Zhang, B., Chen, J., & Han, J. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03589-3 · Cited by 33
Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats
Jakubiak, P., Alvarez‐Sánchez, R., Fueth, M., Broders, O., Kettenberger, H., Stubenrauch, K. G., & Caruso, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01218 · Cited by 24

Authors: del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., Subrizi, A., Turunen, T., Reinisalo, M., Itkonen, J., Toropainen, E., Casteleijn, M., Kidron, H., Antopolsky, M., Vellonen, K.-S., Ruponen, M., & Urtti, A.
Affiliations: University of Helsinki (FI)
University of Eastern Finland (FI)
ORCID: Rimpelä, Anna-Kaisa
Heikkinen, Emma
Kari, Otto K.
Ramsay, Eva
Lajunen, Tatu
Pelkonen, Laura
Bhattacharya, Madhushree
Subrizi, Astrid
Reinisalo, Mika
Itkonen, Jaakko
Toropainen, Elisa
Casteleijn, Marco
Kidron, Heidi
Vellonen, Kati-Sisko
Ruponen, Marika
Urtti, Arto
Venue: Progress in Retinal and Eye Research
Publisher: Elsevier BV
Published: 2017-03
Volume: 57
Pages: 134-185
ISSN: 1350-9462 (ISSN-L)
DOI: 10.1016/j.preteyeres.2016.12.001
OpenAlex: W2567416294
Cited by: 693
References: 476
Citations by year: 2026: 68 · 2025: 96 · 2024: 76 · 2023: 92 · 2022: 74 · 2021: 94 · 2020: 81 · 2019: 59 · 2018: 34 · 2017: 18
FWCI: 3.13
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Progress in Retinal and Eye Research (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Research Explorer (The University of Manchester) (publishedVersion, other-oa)
UEF eRepo (University of Eastern Finland) (submittedVersion)
Työväentutkimus Vuosikirja (submittedVersion)
Funders: Sigrid Juséliuksen Säätiö (64578)
Itä-Suomen Yliopisto
Academy of Finland (263573, 263615, 268868, 272597, 283721)
Tekes (637/31/2015 TEKES)
Seventh Framework Programme
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords: retinal drug delivery, pharmacokinetics, intravitreal injection, systemic drug delivery, topical ocular drug delivery, targeted drug delivery, dosage, tolerability, ocular drug delivery systems
MeSH terms: Animals, Humans, Retina, Retinal Diseases, Tissue Distribution, Drug Delivery Systems, Angiogenesis Inhibitors, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacokinetic aspects of retinal drug delivery

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks